Stock Report

Download full stock data and analysis for free Last Updated: 30-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

JFL Life Sciences Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: JFLLIFE

₹10.75

₹0.00 (0.00%)

As on 28-Aug-2026 09:55IST

Market cap

info icon

₹35 Cr

Revenue (TTM)

info icon

₹131 Cr

P/E Ratio

info icon

5.2

P/B Ratio

info icon

0.8

Div. Yield

info icon

0 %

Edit peer-selector-edit
JFL Life Sciences Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Market cap (₹ Cr)
 35 21,501 19,125 18,253 17,766
Revenue (₹ Cr)
 131 2,570 2,287 3,230 2,432
Net Profit (₹ Cr)
 6.77 735.15 678.07 666.92 169.62
Net Margin (%)
 5.17 26.88 28.10 20.60 6.90
RoE (%)
 15.37 19.16 19.73 18.75 20.76
Price to Earnings
 5.24 29.25 28.74 28.35 104.74
Price-To-Book
 0.76 4.88 5.08 4.51 19.65

Income Statement (₹ Cr)

JFL Life Sciences Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Operating Revenue arrow
131.38 2,519.65 1,937.47 2,893.64 2,275.58
Total Income arrow
131.45 2,707.60 2,033.90 2,912.00 2,304.07
Total Expenditure arrow
119.67 1,615.47 1,290.54 1,876.44 2,013.55
EBITDA arrow
11.71 904.18 646.93 1,017.20 262.03
Depreciation arrow
1.08 57.73 65.96 315.46 28.58
EBIT arrow
10.64 846.45 580.97 701.74 233.45
Interest arrow
2.11 9.57 0.61 231.29 4.49
Other Income arrow
0.07 187.95 96.43 18.36 28.49
Exceptional Items arrow
-- -49.16 -- -- -5.25
Profit before Tax arrow
8.60 975.67 676.78 488.87 252.20
Provision for Tax arrow
2.20 253.24 135.69 114.20 64.68
Profit after Tax arrow
6.40 722.43 541.09 374.67 187.52

Liabilities (₹ Cr)

JFL Life Sciences Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Shareholder's Funds arrow
45.87 4,202.90 2,850.49 2,854.36 872.79
Minority Interest arrow
-- -- 35.90 417.40 --
Non-Current Liabilities arrow
7.39 19.19 13.24 2,100.97 394.49
Current Liabilities arrow
52.99 627.48 305.99 1,489.55 1,109.50
Total Liabilities arrow
106.25 4,921.88 3,207.85 6,862.28 2,414.58

Assets (₹ Cr)

JFL Life Sciences Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Non-Current Assets arrow
14.75 1,046.35 1,071.67 5,531.13 509.16
Current Assets arrow
91.50 3,803.22 2,133.95 1,331.15 1,859.88
Total Assets arrow
106.25 4,921.88 3,207.85 6,862.28 2,414.58
Total Debt* arrow
21.73 2.50 0.55 2,421.66 0.00
Net Current Assets arrow
38.51 3,175.74 1,827.96 -158.40 750.38
Contingent Liabilities arrow
1.34 370.49 0.64 64.29 121.23

Cashflow (₹ Cr)

JFL Life Sciences Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Cash From Operating Activities arrow
-4.33 967.57 432.37 1,065.01 -15.14
Cash Flow from Investing Activities arrow
-3.94 -561.67 -334.73 -79.97 18.69
Cash from Financing Activities arrow
9.10 -798.31 -38.32 -881.32 -91.97
Net Cash Inflow / Outflow arrow
0.83 -392.41 59.32 103.72 -88.42

Ratios

Profitability Ratios

 JFL Life Sciences Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
ROCE (%) arrow
18.20 23.39 26.22 13.59 31.24
ROE (%) arrow
15.00 17.16 21.72 13.81 23.02
ROA (%) arrow
7.19 14.91 18.37 5.48 8.90
EBIT Margin (%) arrow
8.97 43.34 38.37 35.79 12.77
Net Margin (%) arrow
4.87 26.68 26.60 12.87 8.14
Cash Profit Margin (%) arrow
5.69 29.72 31.33 23.22 9.47

Growth Ratios

 JFL Life Sciences Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Revenue Growth (%) arrow
60.14 10.45 14.37 44.02 32.59
EBIT Growth (%) arrow
43.50 19.68 20.21 48.22 -1.38
Net Profit Growth (%) arrow
53.96 -5.88 17.27 -5.65 62.02
EPS Growth (%) arrow
53.96 -5.88 17.25 -10.39 62.02
Book Value Growth (%) arrow
16.26 -0.34 23.77 10.19 13.51

Valuation Ratios

 JFL Life Sciences Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Price / Earnings arrow
4.41 29.89 28.38 54.83 103.45
Price / Book Value arrow
0.62 5.14 5.52 6.78 22.39
Dividend Yield (%) arrow
0.00 1.59 0.30 0.52 0.46
EV/EBITDA arrow
4.12 16.93 19.78 20.75 65.23
Market Cap (₹ Cr) arrow
28.21 21,592.90 15,219.80 19,292.77 19,398.64

Solvency Ratios

 JFL Life Sciences Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Debt to Equity arrow
0.47 0.00 0.00 0.85 0.00
Short term debt to equity ratio arrow
0.30 0.00 0.00 0.14 --
Current Ratio arrow
1.73 6.06 6.97 0.89 1.68
Quick Ratio arrow
1.07 5.31 5.88 0.67 0.75
Interest Coverage arrow
5.08 102.95 1,110.48 3.11 57.17

Operating Efficiency Ratios

 JFL Life Sciences Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Debtors to sales (%) arrow
40.54 7.22 32.65 15.85 9.39
Asset Turnover arrow
1.47 0.54 0.66 0.43 1.08
Receivable days arrow
122.52 26.06 110.70 54.07 31.88
Inventory Days arrow
80.27 65.95 65.86 32.16 126.03
Payable days arrow
74.66 81.01 105.88 140.91 163.79
Cash Conversion Cycle arrow
128.13 11.00 70.68 -54.68 -5.88
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...